Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (528 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-08-02. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: priorto assesskeymonthsrandomization
  Phrases that lowered it: asthmapatients whofev1effectbronchodilator
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 14.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 52.7% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 965 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports with a death: 6.4% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 186 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Number of arms: 6 (lowers risk) · Design
• Maximum age: 75 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma NCT03108027 · started 2017 · scored riskier than 8% of active trials completed
• A Long-term Safety Study of QVM149 in Japanese Patients With Asthma NCT03100825 · started 2017 · scored riskier than 17% of active trials completed
• Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium NCT03158311 · started 2018 · scored riskier than 8% of active trials completed
• Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma NCT02571777 · started 2015 · scored riskier than 20% of active trials completed
• A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma NCT02554786 · started 2015 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.